hPD-1/hCTLA-4(BALB/c)

Nomenclature

BALB/cAnSmoc-Pdcd1tm1(hPDCD1)Ctla4tm1(hCTLA4)Smoc

Cat. NO.

NM-HU-200277

Strain State

Repository Live

Export PDF

Model Description

hPD-1(NM-HU-190079) was crossed with hCTLA4(2)(NM-HU-190078)to generate hPD-1/hCTLA4 mice

Validation Data

1.png

Fig 1.In vivo efficacy study in PD1 & CTLA4 humanized mice. Keytruda, Opdico or Yervoy can inhibit the growth of CT26-hPD-L1 xenografts. The above data indicated that the hPD1/hCTLA4 humanized mouse is an effective model for antineoplastic drug screening.

You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more